<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DNA methylation is one of the major epigenetic changes in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, leading to silencing of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes, with a pathogenetic role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development and progression in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Methylation of key promoter regions, induced by cytotoxic therapy together with complex genetic changes, is important in the biology of therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (t-MN) </plain></SENT>
<SENT sid="2" pm="."><plain>We were interested in the characterization of the methylation pattern of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> de novo and therapy-related </plain></SENT>
<SENT sid="3" pm="."><plain>We studied 385 patients (179 females, 206 males), of a median age of 66 years (range 16-98 years) </plain></SENT>
<SENT sid="4" pm="."><plain>There were 105 MDS, 208 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 72 t-MN (45 MDS and 27 AML) </plain></SENT>
<SENT sid="5" pm="."><plain>Using a methylation-specific PCR, we studied the promoter methylation status of E-cadherin (CDH1), TSP1 and DAP-Kinase 1 </plain></SENT>
<SENT sid="6" pm="."><plain>These genes have been shown to be involved in the <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e>, interfering with <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, interaction with micro-environment, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:chebi fb="0" ids="35703">xenobiotic</z:chebi> detoxification </plain></SENT>
<SENT sid="7" pm="."><plain>We found no associations between promoter hypermethylation and gender or age at the time of initial diagnosis </plain></SENT>
<SENT sid="8" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, there were no associations between hypermethylation and clinical characteristics, including IPSS score, WHO classification and cytogenetics </plain></SENT>
<SENT sid="9" pm="."><plain>DAPK1 was more frequently methylated in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> when compared to de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (39% vs 15.3% and 24.4%, p=0.0001), while methylation of CDH1 was similar in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (51% and 53.4%), but less frequent in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (29%) (p=0.003) </plain></SENT>
<SENT sid="10" pm="."><plain>In the t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> group, we found that the methylation pattern appeared to be related to the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e>, with DAPK1 more frequently methylated in patients with a previous <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> (75% vs 32%, p=0.006) </plain></SENT>
<SENT sid="11" pm="."><plain>On the other hand, methylation of CDH1 was associated to radiotherapy for the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> (84.5% vs 38%, p=0.003) </plain></SENT>
<SENT sid="12" pm="."><plain>TSP1 hypermethylation was rare and not characteristic of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>In 177 patients studied for concurrent methylation of several promoters, t-MN and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> de novo were significantly more frequently hypermethylated in 2 or more promoter regions than de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (20% vs 12.4%, p&lt;0.001) </plain></SENT>
<SENT sid="14" pm="."><plain>Chemotherapy and individual genetic predisposition have a role in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> development, the identification of specific epigenetic modifications may explain complexity and genomic instability of these diseases and give the basis for targeted-therapy </plain></SENT>
<SENT sid="15" pm="."><plain>The significant association with previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> subtypes may underlie a likely susceptibility to methylation of specific targets and a role for constitutional epimutations as predisposing factors for the development of therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
</text></document>